ArticleRheumatology international2026
Lack of association between the Dudley Inflammatory Bowel Symptom Questionnaire and fecal calprotectin in axial spondyloarthritis: a cross-sectional study.
Article in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
To investigate the relationship between gastrointestinal symptom burden assessed by the Dudley Inflammatory Bowel Symptom Questionnaire (DISQ), fecal calprotectin (FC), a non-invasive biomarker suggestive of intestinal inflammation, disease activity, and clinical characteristics in patients with axial spondyloarthritis (axSpA). In this cross-sectional study, 174 patients with axSpA were enrolled. Gastrointestinal symptom burden was assessed using the DISQ, disease activity using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), functional status using the Bath Ankylosing Spondylitis Functional Index (BASFI), and health-related quality of life using the Short Form-36 (SF-36). FC levels were measured by enzyme-linked immunosorbent assay. Correlation analyses, receiver operating characteristic (ROC) analyses, and multivariable logistic regression models were performed. FC levels were normal (< 50 μg/g) in 52.9%, mildly elevated (50-200 μg/g) in 38.5%, and markedly elevated (> 200 μg/g) in 8.6%. DISQ scores demonstrated a moderate positive correlation with BASDAI (rs = 0.432, p < 0.001) and a weak positive correlation with BASFI (rs = 0.248, p < 0.001), while showing moderate inverse correlations with all SF-36 domains (rs = - 0.310 to -0.470, all p < 0.001). In contrast, DISQ scores were not associated with FC levels (rs = 0.066, p = 0.386), ESR (rs = 0.013, p = 0.868), or CRP (rs = 0.029, p = 0.706). ROC analyses demonstrated poor discriminatory performance between DISQ and FC (AUC 0.529 and 0.475, respectively). In multivariable analyses, BASDAI independently predicted clinically significant gastrointestinal symptoms (OR 1.635, 95% CI 1.285-2.081) and elevated FC levels (OR 1.254, 95% CI 1.004-1.567), whereas neither DISQ nor FC independently predicted the other. Gastrointestinal symptom burden assessed by the DISQ was associated with disease activity, functional impairment, and reduced quality of life, but not with FC levels in axSpA.
Indexed as
Identifiers
42696120What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.